Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, L1-050, Boston, MA, 02115, USA.
Department of Radiology, Turku University Hospital and University of Turku, Kiinamyllynkatu 4-8, 20521, Turku, Finland.
Abdom Radiol (NY). 2020 Apr;45(4):1122-1131. doi: 10.1007/s00261-020-02453-2.
To evaluate MRI characteristics in vaginal recurrence of endometrial cancer (EC) including tumor volume shrinkage during salvage radiotherapy, and to identify imaging features associated with survival.
Patients with vaginal recurrence of EC treated with external beam radiotherapy (EBRT) followed by brachytherapy (BT), and with available pelvic MRI at two time points: baseline and/or before BT were retrospectively identified from 2004 to 2017. MRI features including recurrence location and tissue characteristics on T2- and T1-weighted images were evaluated at baseline only. Tumor volumes were measured both at baseline and pre-BT. Survival rates and associations were evaluated by Cox regression and Fisher's exact test, respectively.
Sixty-two patients with 36 baseline and 50 pre-BT pelvic MRIs were included (24/62 with both MRIs). Vaginal recurrence of EC was most commonly located in the vaginal apex (27/36, 75%). Tumors with a post-contrast enhancing peripheral rim or low T2 signal rim at baseline showed longer recurrence-free survival (RFS) (HR 0.2, 95% CI 0.1-0.9, P < 0.05 adjusted for histology; HR 0.2, 95% CI 0.1-0.8, P < 0.05, respectively). The median tumor shrinkage at pre-BT was 69% (range 1-99%). Neither absolute tumor volumes nor volume regression at pre-BT were associated with RFS. Lymphovascular space invasion (LVSI) at hysterectomy and adjuvant RT were associated with recurrence involving the distal vagina (both P < 0.05).
Vaginal recurrences with rim enhancement at baseline MRI predicted improved RFS, while tumor volume shrinkage at pre-BT did not. Distal vaginal recurrence was more common in patients with LVSI and adjuvant RT at EC diagnosis.
评估包括挽救性放疗期间肿瘤体积缩小在内的子宫内膜癌(EC)阴道复发的 MRI 特征,并确定与生存相关的影像学特征。
回顾性地从 2004 年至 2017 年期间,从接受外照射放疗(EBRT)后行近距离放疗(BT)治疗并在两个时间点(基线和/或 BT 前)具有可用盆腔 MRI 的 EC 阴道复发患者中确定了 62 名患者(36 名基线和 50 名 BT 前盆腔 MRI)。仅在基线评估 MRI 特征,包括复发部位和 T2 和 T1 加权图像上的组织特征。在基线和 BT 前均测量肿瘤体积。通过 Cox 回归和 Fisher 确切检验分别评估生存率和相关性。
36 名基线和 50 名 BT 前盆腔 MRI 中包括 62 名患者(24/62 名患者均有 MRI)。EC 阴道复发最常见于阴道顶端(27/36,75%)。基线时具有增强外周缘或低 T2 信号缘的肿瘤具有更长的无复发生存期(RFS)(HR 0.2,95%CI 0.1-0.9,P < 0.05 经组织学调整;HR 0.2,95%CI 0.1-0.8,P < 0.05)。BT 前的中位肿瘤退缩为 69%(范围 1-99%)。BT 前的绝对肿瘤体积或体积退缩均与 RFS 无关。子宫切除术时的淋巴管血管间隙浸润(LVSI)和辅助放疗与阴道远端复发有关(均 P < 0.05)。
基线 MRI 上有边缘增强的阴道复发预测 RFS 改善,而 BT 前的肿瘤体积退缩则没有。在 EC 诊断时具有 LVSI 和辅助放疗的患者中,更常见的是阴道远端复发。